In May 2023, the U.S. Court of Appeals for the Second Circuit ruled in favor of Purdue Pharma’s Chapter 11 Plan of Reorganization (the “Plan”), affirming the Bankruptcy Court’s September 2021 confirmation order and holding that the Plan is appropriate under the law. The Company’s Plan will deliver billions of dollars of value for victim compensation, opioid crisis abatement, and overdose rescue medicines. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners, customers, and consumers.
Rhodes Pharmaceuticals L.P. has developed and distributed quality pharmaceutical products nationwide since 2008. With our R&D capabilities, industry partnerships, broad customer base, and strong relationships with suppliers, we offer reliable supply of high-quality products at competitive prices. Rhodes is a wholly-owned subsidiary of Purdue Pharma L.P.
Our management team has extensive experience in the pharmaceutical industry.
Strong focus on product development of quality products highlighted by exceptional manufacturing and distribution strategies.
Our goal is to provide unparalleled delivery of quality pharmaceutical products while continuing to build lasting relationships within the pharmaceutical community.
We have always been guided by our core values—Collaboration, Integrity, Courage, and Innovation—but now, facing the challenges posed by COVID-19, our core values have taken on new meaning. The health and safety of our colleagues, customers and community, along with the continuity of business operations – critical to serve patients who rely on our medicines and products – are our top priorities.